Comparative Pharmacology
Head-to-head clinical analysis: FYLNETRA versus RYZNEUTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYLNETRA versus RYZNEUTA.
FYLNETRA vs RYZNEUTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYLNETRA (filgrastim-ayow) is a granulocyte colony-stimulating factor (G-CSF) analog that binds to the G-CSF receptor on neutrophils and their precursors, stimulating proliferation, differentiation, and functional activation of neutrophils.
Granulocyte colony-stimulating factor, acts on hematopoietic cells by binding to G-CSF receptors, stimulating proliferation, differentiation, and release of neutrophils.
3.6 mg/kg subcutaneously once daily for up to 14 days. Dose based on absolute neutrophil count.
6 mg subcutaneously once per chemotherapy cycle, administered approximately 24 hours after cytotoxic chemotherapy. Do not administer within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy.
None Documented
None Documented
Terminal elimination half-life approximately 3.5 hours (range 2–5 hours); supports daily dosing in most patients for myelosuppressive chemotherapy.
The terminal elimination half-life is approximately 20–30 hours in healthy volunteers and up to 40 hours in cancer patients receiving chemotherapy, reflecting FcRn-mediated recycling and delayed clearance.
Renal (primarily, as unchanged drug and metabolites, minor biliary/fecal)
Renal clearance accounts for approximately 70% of total clearance, with the remainder via hepatic/biliary/fecal routes. Unchanged drug is minimal as efbemalenograstim alfa is a recombinant fusion protein expected to undergo catabolism to small peptides and amino acids.
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor